Afgeronde publicaties

2018

Germinal centres in diagnostic biopsies of pSS patients are not a risk factor for non-Hodgkin’s lymphoma but a reflection of high disease activity. Haacke EA, van der Vegt B, Vissink A, Spijkervet FKL, Bootsma H, Kroese FGM. Arthritis Rheumatol. 2018 Sep 3. [Epub ahead of print]

Patient-reported change of sensibility and pain after parotid and labial gland biopsy applied for primary Sjögren’s syndrome diagnostics: one-year follow-up study. Delli K, Dagal EF, Bootsma H, Vissink A, Spijkervet FKL. Clin Exp Rheumatol. 2018 May-Jun;36 Suppl 112(3):173-176. 

The role of salivary gland histopathology in primary Sjögren’s syndrome: promises and pitfalls. Frans G.M. Kroese, Erlin A. Haacke, M. Bombardieri. Clin Exp Rheumatol. 2018 May-Jun

Dysregulation of NF-kB in glandular epithelial cells results in Sjögren’s-like features. Wang X, Shaalan A, Liefers S, Coudenys J, Elewaut D, Proctor GB, Bootsma H, Kroese FGM, Pringle S. PLoS One. 2018 Aug.

Dysbiosis of the buccal mucosa microbiome in primary Sjögren’s syndrome patients. van der Meulen TA, Harmsen HJM, Bootsma H, Liefers SC, Vich Vila A, Zhernakova A, Fu J, Wijmenga C, Spijkervet FKL, Kroese FGM, Vissink A. Rheumatology (Oxford). 2018 Jul 27. [Epub ahead of print]

Salivary Gland Stem Cells Age Prematurely in Primary Sjögren’s syndrome. Pringle S, Wang X, Verstappen GMPJ, Terpstra JH, Zhang CK, He A, Patel V, Jones RE, Baird DM, Spijkervet FKL, Vissink A, Bootsma H, Coppes RP, Kroese FGM. Arthritis Rheumatol. 2018 Jul 9. [Epub ahead of print] 

Serum immunoglobulin free light chains are sensitive biomarkers for monitoring disease activity and treatment response in primary Sjögren’s syndrome. Verstappen GM, Moerman RV, van Nimwegen JF, van Ginkel MS, Bijzet J, Mossel E, Vissink A, Hazenberg BPC, Arends S, Kroese FGM, Bootsma H. Rheumatology (Oxford). 2018 Jul 2.  [Epub ahead of print]

The parotid gland connection: ultrasound and biopsies in primary Sjögren’s syndrome.  Mossel E, Delli K, van Nimwegen JF, Stel AJ, Haacke EA, Kroese FGM, Spijkervet FKL, Vissink A, Arends S, Bootsma H. Ann Rheum Dis. 2018 Jul;77(7):e38.

Sialendoscopy enhances salivary gland function in Sjögren’s syndrome: a 6-month follow-up, randomised and controlled, single blind study. Karagozoglu KH, Vissink A, Forouzanfar T, Brand HS, Maarse F, Jager DHJ. Ann Rheum Dis. 2018 Jul;77(7):1025-1031.

Standardisation of the detection of germinal centres in salivary gland biopsies of patients with primary Sjögren’s syndrome is needed to assess their clinical relevance. Haacke EA, van der Vegt B, Vissink A, Spijkervet FKL, Bootsma H, Kroese FGM. Ann Rheum Dis. 2018 Jun;77(6):e32.

Ultrasound of the Major Salivary Glands is a Reliable Imaging Technique in Patients with Clinically Suspected Primary Sjögren’s Syndrome. Delli K, Arends S, van Nimwegen JF, Dijkstra PU, Stel AJ, Spijkervet FKL, Bootsma H, Vissink A. Ultraschall Med. 2018 Jun;39(3):328-333.

Efficacy of Epratuzumab, an Anti-CD22 Monoclonal IgG Antibody, in Systemic Lupus Erythematosus Patients with Associated Sjögren’s Syndrome: Post-hoc Analyses from the EMBODY Trials. Gottenberg JE, Dörner T, Bootsma H, Devauchelle-Pensec V, Bowman SJ, Mariette X, Bartz H, Oortgiesen M, Shock A, Koetse W, Galateanu C, Bongardt S, Wegener WA, Goldenberg DM, Meno-Tetang G, Kosutic G, Gordon C. Arthritis Rheumatol. 2018 May;70(5):763-773.

Scoring hypoechogenic areas in one parotid and one submandibular gland increases feasibility of ultrasound in primary Sjögren’s syndrome. Mossel E, Arends S, van Nimwegen JF, Delli K, Stel AJ, Kroese FGM, Spijkervet FKL, Vissink A, Bootsma H; EULAR US-pSS study group. Ann Rheum Dis.2018 Apr;77(4):556-562.

Reduced salivary secretion contributes more to changes in the oral microbiome of patients with primary Sjögren’s syndrome than underlying disease. van der Meulen TA, Harmsen HJM, Bootsma H, Liefers SC, Vich Vila A, Zhernakova A, Weersma RK, Spijkervet FKL, Kroese FGM, Vissink A. Ann Rheum Dis. 2018 Mar 23.

Is the T Follicular Regulatory / T Follicular Helper Cell Ratio in Blood a Biomarker for Ectopic Lymphoid Structure Formation in Sjögren’s Syndrome? Verstappen GM, Nakshbandi U, Mossel E, Haacke EA, van der Vegt B, Vissink A, Bootsma H, Kroese FGM. Arthritis Rheumatol. 2018 Mar 13.[Epub ahead of print]

Acquisition of N-Glycosylation Sites in Immunoglobulin Heavy Chain Genes During Local Expansion in Parotid Salivary Glands of Primary Sjögren Patients. Visser A, Doorenspleet ME, de Vries N, Spijkervet FKL, Vissink A, Bende RJ, Bootsma H, Kroese FGM, Bos NA. Front Immunol. 2018 Mar 12;9:491.

Can ultrasound of the major salivary glands assess histopathological changes induced by treatment with rituximab in primary Sjögren’s syndrome? Mossel E, Delli K, Arends S, Haacke EA, van der Vegt B, van Nimwegen JF, Stel AJ, Spijkervet FKL, Vissink A, Kroese FGM, Bootsma H. Ann Rheum Dis. 2018 Mar 9.[Epub ahead of print] 

Validation of the ACR-EULAR criteria for Sjögren’s syndrome in a Dutch prospective diagnostic cohort. van Nimwegen JF, van Ginkel MS, Arends S, Haacke EA, Verstappen GM, van der Vegt B, Smitt-Kamminga NS, Spijkervet FKL, Kroese FGM, Vissink A, Bootsma H. Rheumatology (Oxford). 2018 Feb 12.

Th17 cells in primary Sjögren’s syndrome: from plasticity to pathogenicity. Verstappen GM, Corneth OBJ, Bootsma H, Kroese FGM. J Autoimmunity 2018 Feb;87:16-25.

2017

Acquiring new N-glycosylation sites in variable regions of immunoglobulin genes by somatic hypermutation is a commonfeature of autoimmune diseases. Visser A, Hamza N, Kroese FGM, Bos NA. Ann Rheum Dis. 2017 Nov 4. [Epub ahead of print]

Ultrasonography of major salivary glands compared with parotid and labial gland biopsy and classification criteria in patients with clinically suspected primary Sjögren’s syndrome. Mossel E, Delli K, van Nimwegen JF, Stel AJ, Kroese FGM, Spijkervet FKL, Vissink A, Arends S, Bootsma H; EULAR US-pSS Study Group. Ann Rheum Dis. 2017 Nov;76(11):1883-1889.

Germinal centres in diagnostic labial gland biopsies of patients with primary Sjögren’s syndrome are not predictive for parotid MALT lymphoma development. Haacke EA, van der Vegt B, Vissink A, Spijkervet FKL, Bootsma H, Kroese FGM. Ann Rheum Dis. 2017 Oct;76(10):1781-1784.

The value of rituximab treatment in primary Sjögren’s syndrome. Verstappen GM, van Nimwegen JF, Vissink A, Kroese FGM, Bootsma H. Clin Immunol. 2017 Sep;182:62-71.

Attenuation of Follicular Helper T Cell-Dependent B Cell Hyperactivity by Abatacept Treatment in Primary Sjögren’s Syndrome. Verstappen GM, Meiners PM, Corneth OBJ, Visser A, Arends S, Abdulahad WH, Hendriks RW, Vissink A, Kroese FGM, Bootsma H. Arthritis Rheumatol. 2017 Sep;69(9):1850-1861.

FcRL4+ B-cells in salivary glands of primary Sjögren’s syndrome patients. Haacke EA, Bootsma H, Spijkervet FK, Visser A, Vissink A, Kluin PM, Kroese FG. J Autoimmun. 2017 Jul;81:90-98.

Rituximab in the treatment of Sjögren’s syndrome: Is it the wrong drug? Bootsma H, Kroese FG, Vissink A. Arthritis Rheumatol. 2017 Jul;69(7):1346-1349.

Salivary gland ultrasound abnormalities in primary Sjögren’s syndrome: consensual US-SG core items definition and reliability. Jousse-Joulin S, Nowak E, Cornec D, Brown J, Carr A, Carotti M, Fisher B, Fradin J, Hocevar A, Jonsson MV, Luciano N, Milic V, Rout J, Theander E, Stel A, Bootsma H, Vissink A, Baldini C, Baer A, Ng WF, Bowman S, Alavi Z, Saraux A, Devauchelle-Pensec V. RMD Open. 2017 Jun 9

Enhanced Bruton’s tyrosine kinase activity in peripheral blood B lymphocytes of autoimmune disease patients. Corneth OB, Verstappen GM, Paulissen SM, de Bruijn MJ, Rip J, Lukkes M, van Hamburg JP, Lubberts E, Bootsma H, Kroese FG, Hendriks RW. Arthritis Rheumatol. 2017 Jun;69(6):1313-1324. 

Influence of geolocation and ethnicity on the phenotypic expression of primary Sjögren’s syndrome at diagnosis in 8310 patients: a cross-sectional study from the Big Data Sjögren Project Consortium. Brito-Zerón P, Acar-Denizli N, Zeher M, Rasmussen A, Seror R, Theander E, Li X, Baldini C, Gottenberg JE, Danda D, Quartuccio L, Priori R, Hernandez-Molina G, Kruize AA, Valim V, Kvarnstrom M, Sene D, Gerli R, Praprotnik S, Isenberg D, Solans R, Rischmueller M, Kwok SK, Nordmark G, Suzuki Y, Giacomelli R,Devauchelle-Pensec V, Bombardieri M, Hofauer B, Bootsma H, Brun JG, Fraile G, Carsons SE, Gheita TA, Morel J, Vollenveider C, Atzeni F, Retamozo S, Horvath IF, Sivils K, Mandl T, Sandhya P, De Vita S, Sanchez-Guerrero J, van der Heijden E, Trevisani VFM, Wahren-Herlenius M, Mariette X, Ramos-Casals M; EULAR-SS Task Force Big Data Consortium. Ann Rheum Dis. 2017 Jun;76(6):1042-1050.

Physical fatigue characterises patient experience of primary Sjögren’s syndrome. Arends S, Meiners PM, Moerman RV, Kroese FG, Brouwer E, Spijkervet FK, Vissink A, Bootsma H. Clin Exp Rheumatol. 2017 Mar-Apr;35(2):255-261. 

Detailed Analysis of the Articular Domain in Patients with Primary Sjögren Syndrome. Moerman RV, Arends S, Meiners PM, Vissink A, Spijkervet FK, Kroese FG, Brouwer E, Bootsma H. J Rheumatol. 2017 Mar;44(3):292-296.

B Cell Depletion Therapy Normalizes Circulating Follicular Th Cells in Primary Sjögren Syndrome. Verstappen GM, Kroese FG, Meiners PM, Corneth OB, Huitema MG, Haacke EA, van der Vegt B, Arends S, Vissink A, Bootsma H, Abdulahad WH. J Rheumatol. 2017 Jan;44(1):49-58.

2016

Safety of treatments for primary Sjögren’s syndrome. van Nimwegen JF, Moerman RV, Sillevis Smitt N, Brouwer E, Bootsma H, Vissink A. Expert Opin Drug Saf. 2016;15(4):513-24.

Early diagnosis of primary Sjögren’s syndrome: EULAR-SS task force clinical recommendations. Brito-Zerón P, Theander E, Baldini C, Seror R, Retamozo S, Quartuccio L, Bootsma H, Bowman SJ, Dörner T, Gottenberg JE, Mariette X, Bombardieri S, de Vita S, Mandl T, Ng WF, Kruize AA, Tzioufas A, Vitali C, Buyon J, Izmirly P, Fox R, Ramos-Casals M; Eular Sjögren Syndrome Task Force. Expert Rev Clin Immunol. 2016;12(2):137-56.

Sjögren’s syndrome, should we sign? Kroese FG, Verstappen GM, de Leeuw K, Bootsma H. Expert Rev Clin Immunol. 2016;12(4):365-7.

Defining disease activity states and clinically meaningful improvement in primary Sjögren’s syndrome with EULAR primary Sjögren’s syndrome disease activity (ESSDAI) and patient-reported indexes (ESSPRI). Seror R, Bootsma H, Saraux A, Bowman SJ, Theander E, Brun JG, Baron G, Le Guern V, Devauchelle-Pensec V, Ramos-Casals M, Valim V, Dörner T, Tzioufas A, Gottenberg JE, Solans Laqué R, Mandl T, Hachulla E, Sivils KL, Ng WF, Fauchais AL, Bombardieri S, Priori R, Bartoloni E, Goeb V, Praprotnik S, Sumida T, Nishiyama S, Caporali R, Kruize AA, Vollenweider C, Ravaud P, Meiners P, Brito-Zerón P, Vitali C, Mariette X; EULAR Sjögren’s Task Force. Ann Rheum Dis. 2016 Feb;75(2):382-9.

Crying Without Tears: Dimensions of Crying and Relations With Ocular Dryness and Mental Well-Being in Patients With Sjögren’s Syndrome. van Leeuwen N, Bossema ER, Vermeer RR, Kruize AA, Bootsma H, Vingerhoets AJ, Bijlsma JW, Geenen R. J Clin Psychol Med Settings. 2016 Mar;23(1):77-87.

Is YouTube useful as a source of information for Sjögren’s syndrome? Delli K, Livas C, Vissink A, Spijkervet FK. Oral Dis. 2016 Apr;22(3):196-201.

Is salivary gland ultrasonography a useful tool in Sjögren’s syndrome? A systematic review. Jousse-Joulin S, Milic V, Jonsson MV, Plagou A, Theander E, Luciano N, Rachele P, Baldini C, Bootsma H, Vissink A, Hocevar A, De Vita S, Tzioufas AG, Alavi Z, Bowman SJ, Devauchelle-Pensec V; US-pSS Study Group. Rheumatology (Oxford). 2016 May;55(5):789-800.

In primary Sjögren’s syndrome high absolute numbers and proportions of B cells in parotid glands predict responsiveness to rituximab as defined by ESSDAI, but not by SSRI. Delli K, Haacke EA, Kroese FG, Pollard RP, Ihrler S, van der Vegt B, Vissink A, Bootsma H, Spijkervet FK. Ann Rheum Dis. 2016 Jun;75(6):e34.

Need for consensus guidelines to standardise the assessment of germinal centres and other histopathological parameters in salivary gland tissue of patients with primary Sjögren’s syndrome. Delli K, Haacke EA, Ihrler S, van der Vegt B, Vissink A, Bootsma H, Spijkervet FK, Kroese FG. Ann Rheum Dis. 2016 Jun;75(6):e32.

Association of Increased Treg Cell Levels With Elevated Indoleamine 2,3-Dioxygenase Activity and an Imbalanced Kynurenine Pathway in Interferon-Positive Primary Sjögren’s Syndrome. Maria NI, van Helden-Meeuwsen CG, Brkic Z, Paulissen SM, Steenwijk EC, Dalm VA, van Daele PL, Martin van Hagen P, Kroese FG, van Roon JA, Harkin A, Dik WA, Drexhage HA, Lubberts E, Versnel MA. Arthritis Rheumatol. 2016 Jul;68(7):1688-99.

Sjögren syndrome. Brito-Zerón P, Baldini C, Bootsma H, Bowman SJ, Jonsson R, Mariette X, Sivils K, Theander E, Tzioufas A, Ramos-Casals M. Nat Rev Dis Primers. 2016 Jul 7;2:16047.

Parotid Gland Biopsy, the Alternative Way to Diagnose Sjögren Syndrome. Spijkervet FK, Haacke E, Kroese FG, Bootsma H, Vissink A. Rheum Dis Clin North Am. 2016 Aug;42(3):485-99.

Dental Implants in Patients with Sjögren’s Syndrome. Korfage A, Raghoebar GM, Arends S, Meiners PM, Visser A, Kroese FG, Bootsma H, Vissink A. Clin Implant Dent Relat Res. 2016 Oct;18(5):937-945.

Towards personalised treatment in primary Sjögren’s syndrome: baseline parotid histopathology predicts responsiveness to rituximab treatment. Delli K, Haacke EA, Kroese FG, Pollard RP, Ihrler S, van der Vegt B, Vissink A, Bootsma H, Spijkervet FK. Ann Rheum Dis. 2016 Nov;75(11):1933-1938.

Development of the ClinESSDAI: a clinical score without biological domain. A tool for biological studies. Seror R, Meiners P, Baron G, Bootsma H, Bowman SJ, Vitali C, Gottenberg JE, Theander E, Tzioufas A, De Vita S, Ramos-Casals M, Dörner T, Quartuccio L, Ravaud P, Mariette X; EULAR Sjögren Task Force. Ann Rheum Dis. 2016 Nov;75(11):1945-1950.

Abatacept treatment of patients with primary Sjögren’s syndrome results in a decrease of germinal centres in salivary gland tissue. Haacke EA, van der Vegt B, Meiners PM, Vissink A, Spijkervet FK, Bootsma H, Kroese FG. Clin Exp Rheumatol. 2016 Nov 12.

The microbiome-systemic diseases connection. van der Meulen TA, Harmsen H, Bootsma H, Spijkervet F, Kroese F, Vissink A. Oral Dis. 2016 Nov;22(8):719-734.

Influence of geolocation and ethnicity on the phenotypic expression of primary Sjögren’s syndrome at diagnosis in 8310 patients: a cross-sectional study from the Big Data Sjögren Project Consortium. Brito-Zerón P, Acar-Denizli N, Zeher M, Rasmussen A, Seror R, Theander E, Li X, Baldini C, Gottenberg JE, Danda D, Quartuccio L, Priori R, Hernandez-Molina G, Kruize AA, Valim V, Kvarnstrom M, Sene D, Gerli R, Praprotnik S, Isenberg D, Solans R, Rischmueller M, Kwok SK, Nordmark G, Suzuki Y, Giacomelli R, Devauchelle-Pensec V, Bombardieri M, Hofauer B, Bootsma H, Brun JG, Fraile G, Carsons SE, Gheita TA, Morel J, Vollenveider C, Atzeni F, Retamozo S, Horvath IF, Sivils K, Mandl T, Sandhya P, De Vita S, Sanchez-Guerrero J, van der Heijden E, Trevisani VF, Wahren-Herlenius M, Mariette X, Ramos-Casals M; EULAR-SS Task Force Big Data Consortium. Ann Rheum Dis. 2016 Nov 29. pii: annrheumdis-2016-209952.

The transcriptional co-activator Bob1 is associated with pathologic B cell responses in autoimmune tissue inflammation. Levels MJ, Van Tok MN, Cantaert T, Cañete JD, Kroese FG, Germar K, Spits H, Baeten DL, Yeremenko NG. Arthritis Rheumatol. 2016 Dec 1.

Standardisation of labial salivary gland histopathology in clinical trials in primary Sjögren’s syndrome. Fisher BA, Jonsson R, Daniels T, Bombardieri M, Brown RM, Morgan P, Bombardieri S, Ng WF, Tzioufas AG, Vitali C, Shirlaw P, Haacke E, Costa S, Bootsma H, Devauchelle-Pensec V, Radstake TR, Mariette X, Richards A, Stack R, Bowman SJ, Barone F; Sjögren’s histopathology workshop group (appendix) from ESSENTIAL (EULAR Sjögren’s syndrome study group). Ann Rheum Dis. 2016 Dec 13. pii: annrheumdis-2016-210448.

Connective tissue diseases: Refining the classification criteria for primary Sjögren syndrome. Vissink A, Bootsma H. Nat Rev Rheumatol. 2016 Dec 20;13(1):10-12.

2015

EULAR Sjögren’s syndrome disease activity index (ESSDAI): a user guide. Seror R, Bowman SJ, Brito-Zeron P, Theander E, Bootsma H, Tzioufas A, Gottenberg JE, Ramos-Casals M, Dörner T, Ravaud P, Vitali C, Mariette X, Asmussen K, Jacobsen S, Bartoloni E, Gerli R, Bijlsma JW, Kruize AA, Bombardieri S, Bookman A, Kallenberg C, Meiners P, Brun JG, Jonsson R, Caporali R, Carsons S, De Vita S, Del Papa N, Devauchelle V, Saraux A, Fauchais AL, Sibilia J, Hachulla E, Illei G, Isenberg D, Jones A, Manoussakis M, Mandl T, Jacobsson L, Demoulins F, Montecucco C, Ng WF, Nishiyama S, Omdal R, Parke A, Praprotnik S, Tomsic M, Price E, Scofield H, L Sivils K, Smolen J, Laqué RS, Steinfeld S, Sutcliffe N, Sumida T, Valesini G, Valim V, Vivino FB, Vollenweider C. RMD Open. 2015 Feb 20;1(1):e000022.

Aging and Immunopathology in Primary Sjögren’s Syndrome. Bouma HR, Bootsma H, van Nimwegen JF, Haacke EA, Spijkervet FK, Vissink A, Kroese FG. Curr Aging Sci. 2015;8(2):202-13. 

Ig gene analysis reveals altered selective pressures on Ig-producing cells in parotid glands of primary Sjögren’s syndrome patients. Hamza N, Hershberg U, Kallenberg CG, Vissink A, Spijkervet FK, Bootsma H, Kroese FG, Bos NA. J Immunol. 2015 Jan 15;194(2):514-21.

Comment on: Diagnostic accuracies of sialography and salivary ultrasonography in Sjögren’s syndrome patients: a meta-analysis. by Song and Lee (2014). Delli K, Dijkstra PU, Spijkervet FK, Bootsma H, Vissink A. Clin Exp Rheumatol. 2015 Mar-Apr;33(2):293.

Psychological profiles in patients with Sjögren’s syndrome related to fatigue: a cluster analysis. van Leeuwen N, Bossema ER, Knoop H, Kruize AA, Bootsma H, Bijlsma JW, Geenen R. Rheumatology (Oxford). 2015 May;54(5):776-83.

Validation of EULAR primary Sjögren’s syndrome disease activity (ESSDAI) and patient indexes (ESSPRI). Seror R, Theander E, Brun JG, Ramos-Casals M, Valim V, Dörner T, Bootsma H, Tzioufas A, Solans-Laqué R, Mandl T, Gottenberg JE, Hachulla E, Sivils KL, Ng WF, Fauchais AL, Bombardieri S, Valesini G, Bartoloni E, Saraux A, Tomsic M, Sumida T, Nishiyama S, Caporali R, Kruize AA, Vollenweider C, Ravaud P, Vitali C, Mariette X, Bowman SJ; EULAR Sjögren’s Task Force. Ann Rheum Dis. 2015 May;74(5):859-66.

Efficacy of retreatment with rituximab in patients with primary Sjögren’s syndrome. Meiners PM, Arends S, Meijer JM, Moerman RV, Spijkervet FK, Vissink A, Bootsma H. Clin Exp Rheumatol. 2015 May-Jun;33(3):443-4.

The impact of primary Sjögren’s syndrome on female sexual function. van Nimwegen JF, Arends S, van Zuiden GS, Vissink A, Kroese FG, Bootsma H. Rheumatology (Oxford). 2015 Jul;54(7):1286-93.

Diagnostic properties of ultrasound of major salivary glands in Sjögren’s syndrome: a meta-analysis. Delli K, Dijkstra PU, Stel AJ, Bootsma H, Vissink A, Spijkervet FK. Oral Dis. 2015 Sep;21(6):792-800.

Development of the Sjögren’s Syndrome Responder Index, a data-driven composite endpoint for assessing treatment efficacy. Cornec D, Devauchelle-Pensec V, Mariette X, Jousse-Joulin S, Berthelot JM, Perdriger A, Puéchal X, Le Guern V, Sibilia J, Gottenberg JE, Chiche L, Hachulla E, Hatron PY, Goeb V, Hayem G, Morel J, Zarnitsky C, Dubost JJ, Seror R, Pers JO, Meiners PM, Vissink A, Bootsma H, Nowak E, Saraux A. Rheumatology (Oxford). 2015 Sep;54(9):1699-708.

Characterization of systemic disease in primary Sjögren’s syndrome: EULAR-SS Task Force recommendations for articular, cutaneous, pulmonary and renal involvements. Ramos-Casals M, Brito-Zerón P, Seror R, Bootsma H, Bowman SJ, Dörner T, Gottenberg JE, Mariette X, Theander E, Bombardieri S, De Vita S, Mandl T, Ng WF, Kruize A, Tzioufas A, Vitali C; EULAR Sjögren Syndrome Task Force. Rheumatology (Oxford). 2015 Dec;54(12):2230-8.

2014

Xerostomia. Delli K, Spijkervet FK, Kroese FG, Bootsma H, Vissink A. Monogr Oral Sci. 2014;24:109-25.

EULAR Sjogren’s Syndrome Disease Activity Index (ESSDAI) is sensitive to show efficacy of rituximab treatment in a randomised controlled trial. Moerman RV, Arends S, Meiners PM, Brouwer E, Spijkervet FK, Kroese FG, Vissink A, Bootsma H. Ann Rheum Dis. 2014 Feb;73(2):472-4.

Salivary gland biopsy for Sjögren’s syndrome. Delli K, Vissink A, Spijkervet FK. Oral Maxillofac Surg Clin North Am. 2014 Feb;26(1):23-33.

Salivary gland dysfunction and xerostomia in Sjögren’s syndrome. Jensen SB, Vissink A. Oral Maxillofac Surg Clin North Am. 2014 Feb;26(1):35-53.

B-cell hyperactivity in primary Sjögren’s syndrome. Kroese FG, Abdulahad WH, Haacke E, Bos NA, Vissink A, Bootsma H. Expert Rev Clin Immunol. 2014 Apr;10(4):483-99.

Outcome measures for primary Sjögren’s syndrome: a comprehensive review. Seror R, Theander E, Bootsma H, Bowman SJ, Tzioufas A, Gottenberg JE, Ramos-Casals M, Dörner T, Ravaud P, Mariette X, Vitali C. J Autoimmun. 2014 Jun;51:51-6.

Abatacept treatment reduces disease activity in early primary Sjögren’s syndrome (open-label proof of concept ASAP study). Meiners PM, Vissink A, Kroese FG, Spijkervet FK, Smitt-Kamminga NS, Abdulahad WH, Bulthuis-Kuiper J, Brouwer E, Arends S, Bootsma H. Ann Rheum Dis. 2014 Jul;73(7):1393-6.

Autoimmunity: break-through in the diagnosis and treatment of immune-mediated inflammatory diseases. Kroese FG, Baeten D, Huizinga TW. Immunol Lett. 2014 Dec;162(2 Pt B):150-62.

2013

Serum levels of BAFF, but not APRIL, are increased after rituximab treatment in patients with primary Sjogren’s syndrome: data from a placebo-controlled clinical trial. Pollard RP, Abdulahad WH, Vissink A, Hamza N, Burgerhof JG, Meijer JM, Visser A, Huitema MG, Spijkervet FK, Kallenberg CG, Bootsma H, Kroese FG. Ann Rheum Dis. 2013 Jan;72(1):146-8.

Toward new classification criteria for Sjögren’s syndrome? Bootsma H, Spijkervet FK, Kroese FG, Vissink A. Arthritis Rheum. 2013 Jan;65(1):21-3.

[Saliva substitutes not very popular in patients with Sjogren Syndrome]. Vissink A. Ned Tijdschr Tandheelkd. 2013 Jan;120(1):4. Dutch.

Sjögren’s syndrome in older patients: aetiology, diagnosis and management. Moerman RV, Bootsma H, Kroese FG, Vissink A. Drugs Aging. 2013 Mar;30(3):137-53

Classification criteria for Sjogren’s syndrome: we actually need to definitively resolve the long debate on the issue. Vitali C, Bootsma H, Bowman SJ, Dorner T, Gottenberg JE, Mariette X, Ramos-Casals M, Ravaud P, Seror R, Theander E, Tzioufas AG. Ann Rheum Dis. 2013 Apr;72(4):476-8.

Biomarkers: new biomarker for Sjögren’s syndrome–time to treat patients. Kroese FG, Bootsma H. Nat Rev Rheumatol. 2013 Oct;9(10):570-2.

Predominantly proinflammatory cytokines decrease after B cell depletion therapy in patients with primary Sjogren’s syndrome. Pollard RP, Abdulahad WH, Bootsma H, Meiners PM, Spijkervet FK, Huitema MG, Burgerhof JG, Vissink A, Kroese FG. Ann Rheum Dis. 2013 Dec;72(12):2048-50.

2012

How to assess treatment efficacy in Sjögren’s syndrome? Vissink A, Bootsma H, Kroese FG, Kallenberg CG. Curr Opin Rheumatol. 2012 May;24(3):281-9.

Physical activity and physical activity cognitions are potential factors maintaining fatigue in patients with primary Sjogren’s syndrome. Wouters EJ, van Leeuwen N, Bossema ER, Kruize AA, Bootsma H, Bijlsma JW, Geenen R. Ann Rheum Dis. 2012 May;71(5):668-73.

Dealing with emotions when the ability to cry is hampered: emotion processing and regulation in patients with primary Sjögren’s syndrome. van Leeuwen N, Bossema ER, van Middendorp H, Kruize AA, Bootsma H, Bijlsma JW, Geenen R. Clin Exp Rheumatol. 2012 Jul-Aug;30(4):492-8.

Outcome measures for primary Sjögren’s syndrome. Seror R, Bootsma H, Bowman SJ, Dörner T, Gottenberg JE, Mariette X, Ramos-Casals M, Ravaud P, Theander E, Tzioufas A, Vitali C. J Autoimmun. 2012 Aug;39(1-2):97-102.

Immune regulation and B-cell depletion therapy in patients with primary Sjögren’s syndrome. Abdulahad WH, Kroese FG, Vissink A, Bootsma H. J Autoimmun. 2012 Aug;39(1-2):103-11.

Responsiveness of disease activity indices ESSPRI and ESSDAI in patients with primary Sjögren’s syndrome treated with rituximab. Meiners PM, Arends S, Brouwer E, Spijkervet FK, Vissink A, Bootsma H. Ann Rheum Dis. 2012 Aug;71(8):1297-302.

Current and future challenges in primary Sjögren’s syndrome. Vissink A, Bootsma H, Spijkervet FK, Hu S, Wong DT, Kallenberg CG. Curr Pharm Biotechnol. 2012 Aug;13(10):2026-45. 

B-cell populations and sub-populations in Sjögren’s syndrome. Hamza N, Bos NA, Kallenberg CG. Presse Med. 2012 Sep;41(9 Pt 2):e475-83

Systems analysis of primary Sjögren’s syndrome pathogenesis in salivary glands identifies shared pathways in human and a mouse model. Horvath S, Nazmul-Hossain AN, Pollard RP, Kroese FG, Vissink A, Kallenberg CG, Spijkervet FK, Bootsma H, Michie SA, Gorr SU, Peck AB, Cai C, Zhou H, Wong DT. Arthritis Res Ther. 2012 Nov 1;14(6):R238.

Persistence of immunoglobulin-producing cells in parotid salivary glands of patients with primary Sjögren’s syndrome after B cell depletion therapy. Hamza N, Bootsma H, Yuvaraj S, Spijkervet FK, Haacke EA, Pollard RP, Visser A, Vissink A, Kallenberg CG, Kroese FG, Bos NA. Ann Rheum Dis. 2012 Nov;71(11):1881-7.

2011

What have we learned from clinical trials in primary Sjögren’s syndrome about pathogenesis? Kallenberg CG, Vissink A, Kroese FG, Abdulahad WH, Bootsma H. Arthritis Res Ther. 2011 Feb 28;13(1):205.

Serum dehydroepiandrosterone sulphate levels and laboratory and clinical parameters indicating expression of disease are not associated with fatigue, well-being and functioning in patients with primary Sjögren’s syndrome. Hartkamp A, Geenen R, Kruize AA, Bossema ER, Godaert GL, Bootsma H, Bijlsma JW, Derksen RH. Clin Exp Rheumatol. 2011 Mar-Apr;29(2):318-21.

B cell reconstitution and T helper cell balance after rituximab treatment of active primary Sjögren’s syndrome: a double-blind, placebo-controlled study. Abdulahad WH, Meijer JM, Kroese FG, Meiners PM, Vissink A, Spijkervet FK, Kallenberg CG, Bootsma H. Arthritis Rheum. 2011 Apr;63(4):1116-23.

Identification of autoantibody biomarkers for primary Sjögren’s syndrome using protein microarrays. Hu S, Vissink A, Arellano M, Roozendaal C, Zhou H, Kallenberg CG, Wong DT. Proteomics. 2011 Apr;11(8):1499-507.

EULAR Sjogren’s Syndrome Patient Reported Index (ESSPRI): development of a consensus patient index for primary Sjogren’s syndrome. Seror R, Ravaud P, Mariette X, Bootsma H, Theander E, Hansen A, Ramos-Casals M, Dörner T, Bombardieri S, Hachulla E, Brun JG, Kruize AA, Praprotnik S, Tomsic M, Gottenberg JE, Devauchelle V, Devita S, Vollenweider C, Mandl T, Tzioufas A, Carsons S, Saraux A, Sutcliffe N, Vitali C, Bowman SJ; EULAR Sjögren’s Task Force. Ann Rheum Dis. 2011 Jun;70(6):968-72.

Treatment of mucosa-associated lymphoid tissue lymphoma in Sjogren’s syndrome: a retrospective clinical study. Pollard RP, Pijpe J, Bootsma H, Spijkervet FK, Kluin PM, Roodenburg JL, Kallenberg CG, Vissink A, van Imhoff GW. J Rheumatol. 2011 Oct;38(10):2198-208.

Treatment of primary Sjögren’s syndrome with anti-CD20 therapy (rituximab). A feasible approach or just a starting point? Meiners PM, Vissink A, Kallenberg CG, Kroese FG, Bootsma H. Expert Opin Biol Ther. 2011 Oct;11(10):1381-94.

2010

[Autoimmune sialadenitis]. Guntinas-Lichius O, Vissink A, Ihrler S. HNO. 2010 Mar;58(3):200-10.

Effectiveness of rituximab treatment in primary Sjögren’s syndrome: a randomized, double-blind, placebo-controlled trial. Meijer JM, Meiners PM, Vissink A, Spijkervet FK, Abdulahad W, Kamminga N, Brouwer E, Kallenberg CG, Bootsma H. Arthritis Rheum. 2010 Apr;62(4):960-8.

Accurate detection of changes in disease activity in primary Sjögren’s syndrome by the European League Against Rheumatism Sjögren’s Syndrome Disease Activity Index. Seror R, Mariette X, Bowman S, Baron G, Gottenberg JE, Bootsma H, Theander E, Tzioufas A, Vitali C, Ravaud P; European League Against Rheumatism Sjögren’s Task Force. Arthritis Care Res (Hoboken). 2010 Apr;62(4):551-8. Erratum in: Arthritis Care Res (Hoboken). 2013 Aug;65(8):1392. Bootsma, Hendrika [corrected to Bootsma, Hendrika].

EULAR Sjogren’s syndrome disease activity index: development of a consensus systemic disease activity index for primary Sjogren’s syndrome. Seror R, Ravaud P, Bowman SJ, Baron G, Tzioufas A, Theander E, Gottenberg JE, Bootsma H, Mariette X, Vitali C; EULAR Sjögren’s Task Force. Ann Rheum Dis. 2010 Jun;69(6):1103-9. Erratum in: Ann Rheum Dis. 2011 May;70(5):880.

[Theses 25 years after date 23. Developments in the prevention and treatment of xerostomia]. Vissink A. Ned Tijdschr Tandheelkd. 2010 Sep;117(9):453-9. Dutch.

Preclinical validation of salivary biomarkers for primary Sjögren’s syndrome. Hu S, Gao K, Pollard R, Arellano-Garcia M, Zhou H, Zhang L, Elashoff D, Kallenberg CG, Vissink A, Wong DT. Arthritis Care Res (Hoboken). 2010 Nov;62(11):1633-8.

Treatment approaches in primary Sjogren syndrome. Vissink A, Kallenberg CG, Bootsma H. JAMA. 2010 Nov 10;304(18):2015-6; author reply 2016.

2009

Systems biology analysis of Sjögren’s syndrome and mucosa-associated lymphoid tissue lymphoma in parotid glands. Hu S, Zhou M, Jiang J, Wang J, Elashoff D, Gorr S, Michie SA, Spijkervet FK, Bootsma H, Kallenberg CG, Vissink A, Horvath S, Wong DT. Arthritis Rheum. 2009 Jan;60(1):81-92.

Treatment of primary Sjogren syndrome with rituximab: extended follow-up, safety and efficacy of retreatment. Meijer JM, Pijpe J, Vissink A, Kallenberg CG, Bootsma H. Ann Rheum Dis. 2009 Feb;68(2):284-5.

Increased frequency of CD16+ monocytes and the presence of activated dendritic cells in salivary glands in primary Sjögren syndrome. Wildenberg ME, Welzen-Coppens JM, van Helden-Meeuwsen CG, Bootsma H, Vissink A, van Rooijen N, van de Merwe JP, Drexhage HA, Versnel MA. Ann Rheum Dis. 2009 Mar;68(3):420-6.

Health-related quality of life, employment and disability in patients with Sjogren’s syndrome. Meijer JM, Meiners PM, Huddleston Slater JJ, Spijkervet FK, Kallenberg CG, Vissink A, Bootsma H. Rheumatology (Oxford). 2009 Sep;48(9):1077-82.

Clinical and histologic evidence of salivary gland restoration supports the efficacy of rituximab treatment in Sjögren’s syndrome. Pijpe J, Meijer JM, Bootsma H, van der Wal JE, Spijkervet FK, Kallenberg CG, Vissink A, Ihrler S. Arthritis Rheum. 2009 Nov;60(11):3251-6.

2008

Effect of dehydroepiandrosterone administration on fatigue, well-being, and functioning in women with primary Sjögren syndrome: a randomised controlled trial. Hartkamp A, Geenen R, Godaert GL, Bootsma H, Kruize AA, Bijlsma JW, Derksen RH. Ann Rheum Dis. 2008 Jan;67(1):91-7.

Sjögren’s syndrome and localized nodular cutaneous amyloidosis: coincidence or a distinct clinical entity? Meijer JM, Schonland SO, Palladini G, Merlini G, Hegenbart U, Ciocca O, Perfetti V, Leijsma MK, Bootsma H, Hazenberg BP. Arthritis Rheum. 2008 Jul;58(7):1992-9.

2007

Progression of salivary gland dysfunction in patients with Sjogren’s syndrome. Pijpe J, Kalk WW, Bootsma H, Spijkervet FK, Kallenberg CG, Vissink A. Ann Rheum Dis. 2007 Jan;66(1):107-12.

Parotid gland biopsy compared with labial biopsy in the diagnosis of patients with primary Sjogren’s syndrome. Pijpe J, Kalk WW, van der Wal JE, Vissink A, Kluin PM, Roodenburg JL, Bootsma H, Kallenberg CG, Spijkervet FK. Rheumatology (Oxford). 2007 Feb;46(2):335-41.

Lacrimal punctum occlusion in the treatment of severe keratoconjunctivitis Sicca caused by Sjögren syndrome: a uniocular evaluation. Mansour K, Leonhardt CJ, Kalk WW, Bootsma H, Bruin KJ, Blanksma LJ; Sjögren Workgroup. Cornea. 2007 Feb;26(2):147-50.

Salivary gland parameters and clinical data related to the underlying disorder in patients with persisting xerostomia. van den Berg I, Pijpe J, Vissink A. Eur J Oral Sci. 2007 Apr;115(2):97-102.

The future of biologic agents in the treatment of Sjögren’s syndrome. Meijer JM, Pijpe J, Bootsma H, Vissink A, Kallenberg CG. Clin Rev Allergy Immunol. 2007 Jun;32(3):292-7.

Salivary proteomic and genomic biomarkers for primary Sjögren’s syndrome. Hu S, Wang J, Meijer J, Ieong S, Xie Y, Yu T, Zhou H, Henry S, Vissink A, Pijpe J, Kallenberg C, Elashoff D, Loo JA, Wong DT. Arthritis Rheum. 2007 Nov;56(11):3588-600.

[Saliva diagnosis: the future becomes the present reality]. Vissink A, Veerman EC, van Nieuw Amerongen A. Ned Tijdschr Tandheelkd. 2007 Nov;114(11):468-73. Dutch.